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The success of a twice-weekly regimen of streptomycin plus isoniazid, reported earlier
from the Tuberculosis Chemotherapy Centre, Madras, prompted an investigation at the
Centre of various once-weekly regimens of chemotherapy. In this context, a pilot study was
undertaken in 19 patients to assess the toxicity of high-dosage pyrazinamide (70 mg/kg of
body-weight), when administered once weekly, together with isoniazid (14 mg/kg of body-
weight) and streptomycin (1 g), for at least 6 months. Serial estimations of SGOT and
SGPT activity, urine tests for urobilin and bilirubin and haematological investigations were
undertaken at frequent intervals. None of the patients showed any clinical evidence of
hepatotoxicity ; however, there was a slight and transient elevation in aminotransferase
activity, probably of a non-specific nature, at 2 weeks. These findings are encouraging for
the use of high-dosage pyrazinamide in once-weekly regimens of chemotherapy.
INTRODUCTION
Intermittent chemotherapy with 1 g of strepto-
mycin plus isoniazid in high dosage (approximately
14 mg/kg of body-weight), both drugs being given
together twice weekly, has been found to be highly
effective in the treatment of pulmonary tuberculosis
at this Centre (Tuberculosis Chemotherapy Centre,
Madras, 1964; Nazareth et a!., 1966). Since a
regimen with a longer interval between the doses
would offer further practical advantages, a study was
planned to investigate the principle of once-weekly
chemotherapy. One of the regimens in this study was
streptomycin plus isoniazid plus pyrazinamide, all
three drugs given together once a week. It was pro-
posed to administer the pyrazinamide also in a high
dosage, but since the drug is hepatotoxic in con-
ventional daily dosages (McDermott et al., 1954;
Morrissey & Rubin, 1959; United States Public
Health Service, 1959), a pilot study was undertaken
to assess its toxicity when administered once weekly
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in a dosage of approximately 70 mg/kg of body
weight, together with 1 g of streptomycin and 14 mg
of isoniazid per kg of body-weight.
This paper reports the findings in 19 patients with
bacteriologically confirmed pulmonary tuberculosis,
none of whom had received pyrazinamide pre-
viously. Of these, 14 were males; 13 were aged
35 years or more. On admission, 3 patients weighed
less than 70 lb (31.75 kg), 7 weighed 70 lb–89 lb
(31.75 kg–40.4 kg) and 9 weighed 90 lb (40.8 kg) or
more.
Treatment regimen
Once a week, all patients received 1 g of strepto-
mycin (irrespective of body-weight), 14 mg of
isoniazid per kg of body-weight and pyrazinamide
(as in the schedule below):
Body-weight
(lb) [ Approx.
Pyrazinamide dosage
equivalent]  ( g )
<70 [ < 32 ] 2.0
70–89 [32–401 2.5
> 90 [ > 40] 3.0
The mean initial dosage of pyrazinamide was
68 mg/kg, the range being 55 mg/kg to 78 mg/kg.
If, at a monthly examination, a patient was found
to have gained weight since the previous monthly
examination and moved into a higher weight
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category, the dosage of pyrazinamide was increased;
however, the dosage was not decreased for loss in
weight.
Duration of treatment
The regimen was prescribed for 6 months in the
first instance. Subsequently, it was continued up to
12 months unless the clinical, radiographic or bac-
teriological tidings warranted a change of chemo-
therapy. In the event, 4 patients had their treatment
changed at 6 months, 1 at 7 months and 3 at 11
months; thus, only 11 patients completed the year
of treatment.
Management
The patients were managed on an ambulatory
basis and attended the clinic once a week, at which
time they swallowed a dose of isoniazid and of pyra-
zinamide under the supervision of a clinic nurse; they
then received an injection of streptomycin. Patients
were not interrogated to elicit symptoms of side-
effects from the drugs but all spontaneous com-
plaints were recorded.
Investigations
Routine clinical, radiographic and bacteriological
examinations were undertaken at monthly intervals
during the year. In addition, the following investiga-
tions were undertaken to assess toxicity :
(1) Serum L-aspartate : 2-oxoglutarate amino-
transferase 1 (serum glutamic-oxaloacetic transami-
nase; SCOT) activity and serum L-alanine : 2-oxo-
glutarate aminotransferase 1 (serum glutamic-pyruvic
transaminase; SGPT) activity, were determined on
specimens of blood collected (a) before the start of
chemotherapy, (b) on days 1 and 8 (i.e., about
24 hours after the first and second doses, respectively)
and (c) at 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24 weeks
after the start of treatment and at intervals. of
4 weeks thereafter (immediately before the admin-
istration of the dose of pyrazinamide on that day).
The SGOT and SGPT activities were determined
by employing the procedures described by the Sigma
Chemical Company (1961), and were expressed in
Karmen units. Since normal values of SGOT and
SGPT activity are defined as 8-40 units and 5-35 units,
respectively, and values of 40-50 and 35-45 units,
respectively, are regarded as border-line (see Sigma
Chemical Company, 1961), SGOT values of over
1  Te rmino logy  r ecommended  by  t he  Commiss ion  on
Enzymes of the International Union of Biochemistry (Florkin
& Stotz. 1965).
50 units and SGPT values of over 45 units have
been regarded as abnormal in the present study.
(2) A test for the presence of bilirubin (Sobotka et
al., 1953) and a spectroscopic examination for
urobilin (Harrison, 1957) were undertaken in urine
specimens collected at weekly intervals.
(3) Estimations of the haemoglobin and packed
cell volume (PCV) were undertaken before the start
of chemotherapy, at 1, 2, 3, 4, 6, 8, 10 and 12 weeks,
and at intervals of 4 weeks thereafter.
Clinical toxicity
RESULTS
There was no clinical evidence of liver toxicity in
any of the 19 patients. Vomiting, following the
administration of the drugs, was the only complaint
recorded, and occurred once in 1 patient and 3 times
in 2 others.
Serum aminotransferase activity in the first 6 months
SGOT. The mean SGOT activity on admission
was 27 units, the range being 14-54 units (see accom-
panying table). With the commencement of treat-
SGOT AND SGPT VALUES ON ADMISSION
AND DURING TREATMENT
Time of blood
collection
On admission
1 day
8 days
2 weeks
3 weeks
4 weeks
6 weeks
8 weeks
10 weeks
12 weeks
16 weeks
20 weeks
24 weeks
28 weeks
32 weeks
35 weeks
40 weeks
44 weeks
48 weeks
52 weeks
No. of
patients
examineda
19
17
19
17
19
18
18
18
19
18
18
19
19
SGOT activity
(Karmen units)
Mean Range
27
28
31
34
28
30
28
24
29
29
29
25
30
14-54 15
15-52 15
17-74 18
17-52 24
13-48 19
13-84 21
11-71 14
16-36 13
18-69 14
15-60 13
13-56 11
10-49 9
19-53 15
16-52 14
20-56 16
31-48 20
18-46 15
16-49 15
22-49 17
22-72 18
SGPT activity
(Karmen units)
Mean Range
6-31
6-37
2-58
4-43
5-42
8-63
2-56
0-24
0-54
0-34
0-26
0-31
4-42
0-43
7-31
9-31
4-37
0-30
4-38
4-38
a Patients who had a change of chemotherapy on account
of clinical or radiographic deterioration or the bacteriological
results have been included up to the time of change.
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MEAN SERUM AMINOTRANSFERASE ACTIVITY ON ADMISSION AND DURING 24 WEEKS OF TREATMENT
ment, the mean SGOT activity showed a significant
increase to 34 units at 2 weeks (P = 0.02), followed
immediately by a decrease to almost the value on
admission (see accompanying figure).
Considering the findings in individual patients
(not tabulated here), an SGOT value of higher than
50 units was repeatedly obtained during treatment
(namely, on 8 of 12 occasions) in only 1 patient;
however, this patient had an SGOT value of 54 units
on admission. Only 4 others had a value higher than
50 units during treatment, all on 1 occasion only–1 at
8 days, 2 at 2 weeks and 1 at 4 weeks. Finally, in
none of the patients did the treatment mean (that is,
the mean of all values during treatment) exceed the
value on admission by 10 units or more..
SGPT. The mean SGPT activity was 15 units on
admission, the range being 6-31 units (see accom-
panying table). It increased significantly (P < 0.01) to
24 units at 2 weeks, was still high at 4 weeks (21 units)
but decreased subsequently to the mean value at the
time of admission.
The patient with an SGOT of higher than 50 units
on admission had an SGPT of 31 units at this time,
and an SGPT of higher than 45 units in 3 of 12 spe-
cimens collected during treatment. Only 2 other
patients had an SGPT of higher than 45 units during
treatment, both on 1 occasion only (at 8 days and
4 weeks) and both associated with an SGOT activity
of more than 50 units. Finally, in none of the patients
did the treatment mean exceed the value on admis-
sion by 10 units or more.
Serum aminotransferase activity in patients who con-
tinued to receive the prescribed regimen up to 12
months
Of the 11 patients who received the prescribed
regimen for 12 months, none had clinical evidence
of liver damage. The mean SGOT activities in these
patients were 32, 34, 33 and 34 units at 0, 12, 24 and
52 weeks, respectively; the corresponding mean
SGPT values were 17, 15, 18 and 18, respectively.
Between 24 and 52 weeks, the SGOT value was
higher than 50 units in only 2 patients, one at 28 and
32 weeks, and the other (who had a value of 54 units
on admission) at 32 weeks; the SGPT value was
higher than 45 units in none.
Bilirubin and urobilin in urine
Only 2 urine specimens were positive for bilirubin.
Both were obtained in the first month and from the
same patient. Positive results for urobilin were
obtained from 2 others, both in the third month.
All the 3 patients had SGOT values of 50 units or
less at the time; they continued to receive the regimen
for 52 weeks and had no evidence of toxicity.
Haematological examinations
The mean haemoglobin value was 12.9 g per 100 ml
on admission, and steadily increased to 13.0 g at
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12 weeks; 13.8 g at 24 weeks and 14.3 g at 52 weeks.
The corresponding PCV values were 39%, 39%,
42% and 41%, respectively.
DISCUSSION
Hepatotoxicity resulting from daily administra-
tion of pyrazinamide has been reported by earlier
workers (McDermott et al., 1954; Morrissey &
Rubin, 1959; Allison, 1959). The United States
Public Health Service (1959) showed that the in-
cidence of hepatotoxicity due to pyrazinamide was
related to the daily dosage of the drug; thus, 4.8%
of 167 patients who received 40 mg of pyrazinamide
per kg of body-weight for 24 weeks developed
clinical evidence of hepatic damage, as compared
with only 1.2 % of 160 patients who received 25 mg/kg
of body-weight for the same duration. At this Centre,
however, there was no clinical evidence of hepato-
toxicity in a group of South Indian patients treated
with a daily regimen of pyrazinamide ranging from
26 mg to 43 mg/kg of body-weight (average, 33.0
mg/kg) plus streptomycin for 1-2, years (Velu et al.,
1961).
The present study was undertaken in 19 patients
to determine the incidence of toxicity with once-
weekly pyrazinamide in a dose of approximately
70 mg/kg of body-weight. Routine estimations of
serum aminotransferase activity, reported to be of
value in the early detection of hepatotoxicity due to
pyrazinamide (Wingo et al., 1957), were undertaken
for all patients at frequent intervals. There was a rise
in the mean SGOT and SGPT values at 2 weeks
followed by a fall to the values recorded on admis-
sion. It is possible that this rise in the aminotransferase
activity at 2 weeks may be of a non-specific nature,
similar to the transient rise in aminotransferase
activity observed with drugs such as penicillin,
viomycin and p-aminosalicylic acid (Morrissey &
Rubin, 1959), and with oral contraceptives, certain
hypotensive and vasodilator drugs, and carbenoxo-
lone sodium (Sherlock, 1968). Excluding the patient
who had a high SGOT value on admission, 4
patients showed a rise in SGOT activity to greater
than 50 units during treatment, all on 1 occasion;
the corresponding number showing a rise in SGPT
activity to more than 45 units was 2, both showing
it on 1 occasion only.
In conclusion, there was no clinical evidence of
hepatotoxicity; however, there was a slight and
transient elevation in aminotransferase activity at
2 weeks, which could have been of a non-specific
nature. Haematological investigations showed no
evidence of anaemia, nor did urine tests for bilirubin
and urobilin show any evidence of toxicity.
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Des études menées au Centre de Chimiothérapie de la
tuberculose de Madras, Inde, ont montré qu’adminis-
trée à raison de deux fois par semaine, la chimiothérapie
intermittente au moyen d'une association de streptomy-
cine et de hautes doses d’isoniazide (environ 14 mg par
kg de poids corporel) donnait d’excellents résultats dans
le traitement de la tuberculose pulmonaire. Etant donné
qu’il y aurait de reels avantages à prolonger encore l’in-
tervalle séparant les prises de médicament, il a été décidé
d’étudier des thérapeutiques susceptibles d’être adminis-
trées une fois par semaine. L’un des traitements proposes
comportait l’administration de pyrazinamide à hautes
doses, mais ce médicament étant hépatotoxique aux doses
quotidiennes usuelles, il était important d’évaluer sa
toxicité lorsqu’il était administré une fois par semaine à
raison d’environ 70 mg/kg en association avec la strep-
tomycine et l’isoniaxide.
On a constitué un groupe de 19 malades dont 13 âgés
de 35 am ou plus, comprenant 14 hommes, atteints de
tuberculose pulmonaire confirmée par les examens bac-
tériologiques et dont aucun n’avait encore été traité à la
pyrazinamide. Les malades se présentaient une fois par
semaine dans un dispensaire et recevaient, sous surveil-
lance, de la streptomycine (1 g), de l’isoniazide (14 mg/kg)
et de la pyrazinamide (dose initiale moyenne: 68 mg/kg,
variation: 55 mg/kg à 78 mg/kg). Le traitement a tout
d’abord duré six mois, mais ensuite on l’a continue
pendant six mois encore chez 11 sujets.
Les malades ont été régulièrement soumis chaque mois
à des examens bactériologiques, radiographiques et
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cliniques et toutes les plaintes concernant des effets se-
condaires formulées spontanément ont été consignees. En
outre, les examens suivants ont été effectués en vue d’éva-
luer l’hépatotoxicité de la medication: a) épreuves d’ac-
tivité de la transaminase glutamique-oxalacétique (SGOT)
et de la transaminase glutamique-pyruvique (SGPT);
b) recherche de la bilirubine et de l’urobiline, et c) éva-
luation du taux d’hémoglobine et du volume globulaire
à l’hématocrite.
Les épreuves n’ont révélé de manifestation clinique
d’hépatotoxicité chez aucun des 19 malades; les médica-
ments n’ont pas eu d’autres effets secondaires que quelques
vomissements: une fois chez un malade et trois fois chez
deux autres. Les valeurs de la SGOT et de la SGPT ont
augmenté de façon significative au cours des deux pre-
mières semaines du traitement, mais elles sont ensuite
redescendues aux environs de la valeur moyenne enre-
gistrée avant le début du traitement. Aucun des 11 ma-
Jades dont le traitement a été poursuivi pendant 12 mois
n’a présenté de signes cliniques de toxicité hépatique.
On a trouvé deux échantillons d’urine contenant de la
bilirubine pendant le premier mois de traitement chez un
malade et la recherche de l’urobilme a été positive chez
deux autres au cours du troisième mois, mais on a pour-
suivi leur traitement sans constater aucune manifestation
d’hépatotoxicité. Le taux moyen d’hémoglobine dans le
sang des malades était de 12 g/100 ml au moment de l’ad-
mission; il est month à 13 g à la 12e semaine, 13,8 g à
la 24e semaine et 14,3 g à la 52e semaine; les chiffres
correspondants pour le volume globulaire étaient de
39%, 39%, 42% et 41%.
Il apparait donc que si la pyrazinamide peut être
hépatotoxique aux doses quotidiennes usuelles, les exa-
mens de laboratoire n’ont fourni que peu d’indications
d’hépatotoxicité lorsque le médicament était administré
à des doses hebdomadaires élevées (environ 70 mg/kg).
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